Metabolic imaging identifies ovarian cancer subtypes and predicts chemotherapy response

A new study shows that metabolic imaging can differentiate between subtypes of high-grade serous ovarian cancer (HGSOC) based on their oxidative phosphorylation (OXPHOS) levels. This technique helps identify early responses to chemotherapy, enhancing treatment precision. The research found that high OXPHOS subtypes are more responsive to chemotherapy, while low OXPHOS subtypes show resistance. The study used patient-derived organoids and advanced imaging methods to assess metabolic differences and treatment responses. Metabolic imaging offers a promising alternative to traditional biopsies, improving the detection of OXPHOS activity in tumors. This advancement may lead to better predictions of treatment outcomes for ovarian cancer patients.